Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Allergen immunotherapy refers to the repeated administration of allergen extracts to allergic individuals to offer long-term relief of symptoms and improvement in quality of life during succeeding natural allergen exposure. Allergen immunotherapy is effective in IgE-mediated disease in patients with a limited spectrum (1 or 2) of allergies. In the USA, over 7.5% of the people eighteen years of age or above experience allergic rhinitis or hay fever. A significant percentage of children also suffers from hay fever. Allergic rhinitis affects ten to thirty percent of the population across the globe. Further, over five percent of children across the world experience some kind of food allergy. Globally, increase in prevalence of allergic diseases has continued in the industrialized world for over fifty years. Such prevalence of allergic conditions is expected to drive the global allergy immunotherapy market. North America, Europe and Asia Pacific are likely to be key markets.
In 2019, Adamis Pharmaceuticals Corporation announced that its marketing and commercial partner, Sandoz Inc. (Sandoz) had launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. Sandoz launched the medicine as a reasonably priced, single-dose, pre-filled syringe alternative to epinephrine auto-injectors. Such developments are expected to boost the global allergy immunotherapy market.
In 2022, a study showed no evidence that women felt adverse events in their pregnancies if they had been treated with allergen-specific immunotherapy (AIT) three months before conception up to gestational week 22.
In 2022, a clinical trial funded by the National Institutes of Health revealed that giving peanut oral immunotherapy to highly peanut-allergic children aged 1 to 3 years safely desensitized majority of them to peanut and brought about remission of peanut allergy in one-fifth. The results of the IMPACT trial suggested a window of opportunity in early childhood to induce remission of peanut allergy through oral immunotherapy. It is noteworthy that peanut allergy affects nearly two percent of the children in USA, or about 1.5 million individuals aged 17 years and younger. The risk of a life-threatening allergic reaction to accidentally eaten peanut was significant for these children, most of which remain peanut-allergic for life.
Key Findings of the Report:
Market Analysis by Allergy, Treatment, Distribution Channel and Region:
Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.
EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.
Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790
*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.